AD
Business activity cleared — no excluded categories detected
Source: stored filing inputs · Balance sheet as of 2025-06-30 · Income statement as of 2025-06-30
Addex Therapeutics Ltd (ADXN) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-06). See the full ratio breakdown and business-activity screen below for the reasoning.
Research only, not the primary verdict above — computed from SEC EDGAR filings and business-activity classification, same as the Discord bot's !halal command.
Business activity: cleared (no excluded categories detected)
Source: stored filing inputs · Balance sheet as of 2025-06-30 · Income statement as of 2025-06-30
⚠️ These two accepted standards disagree for this stock.
Combined verdict: AAOIFI Non Compliant Usmani Needs Review Dow Jones Islamic Needs Review S&P Shariah Needs Review MSCI Islamic Needs Review MSCI Islamic M Needs Review FTSE Shariah Needs Review
ℹ️ AAOIFI screens this company as Non-Compliant on the financial ratios alone — a ratio failure is decisive on its own, so those verdicts stand regardless of what the business-activity screen concluded.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 28.10 | BUY |
| Stochastic %K (14) | 0.00 | BUY |
| CCI (20) | -75.15 | NEUTRAL |
| Williams %R (14) | -100.00 | BUY |
| MACD (12,26,9) | -0.04 | SELL |
| ROC (10) | -19.86 | SELL |
| Momentum (10) | -0.84 | SELL |
| EMA (10) | 3.78 | SELL |
| SMA (10) | 3.68 | SELL |
| EMA (20) | 4.22 | SELL |
| SMA (20) | 4.38 | SELL |
| EMA (30) | 4.56 | SELL |
| SMA (30) | 4.81 | SELL |
| EMA (50) | 5.01 | SELL |
| SMA (50) | 5.23 | SELL |
| EMA (100) | 5.68 | SELL |
| SMA (100) | 5.90 | SELL |
| EMA (200) | 6.65 | SELL |
| SMA (200) | 6.67 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Background via Yahoo Finance — informational, not part of the verdict.
🔴 AVOID
The main driver: lagging the market by 32.5%, analyst consensus is bearish. Too many signals pointing the wrong way. Wait for the picture to improve before committing capital.
Scores: 0 bullish / 3 bearish
No real edge — avoid
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | RANGING | 45 |
| ⏰ 4H | NEUTRAL | 16 |
| 🕐 1H | RANGING | 64 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
